MUMBAI, India, Sept. 14 -- Intellectual Property India has published a patent application (202617067185 A) filed by Oso Medical, Inc. on May 28, 2026, for Method, Device, And System For Pre-Biased Tissue With Lower-Energy Irreversible Electroporation And Tissue Identification For Pulse Field Immunotherapy.
Inventors include Demarais, Denise; Mane, Rohit Chandrakant; Crook, Jeffery; Friedrichs, Paul; and Alinezhadbalalami, Nastaran.
The application for the patent was published on September 11, 2026, under issue no. 37/2026.
Abstract: Several new inventions are detailed with this system, method, and device. While at the core, these inventions may ablate tissue by application of a short duration electric field, the therapy waveform used to apply the electric field is novel and optimized to preserve the intra-cellular content possible across different identified tissues. The optimized pulse biases tissue to an electroporation state and then presents a "hammer pulse" which may be along the same polarity or different polarity. This treatment minimizes thermal effects and is being defined as Pulse Field Immunotherapy (PFI). The antigens are left in situ and taken up by antigen-presenting cells in the periphery allowing the immune system to engage. Additional tissue feedback is obtained through an invention that performs measurements on tissue to determine its composition while the applicator is inserted into normal tissue, followed by diseased tissue. Tissue composition is compared against a library of characterized Tissue Identity Profiles (TIPs), allowing for immediate assessments and therapy to be provided while the patient is undergoing traditional diagnosis.
Disclaimer: Curated by HT Syndication.
